Stayble Therapeutics

Stayble Therapeutics is developing a truly innovative, non-surgical product (STA-363) to permanently alleviate discogenic chronic low back pain (cLBP). Discogenic cLBP is globally one of the costliest and most disabling medical conditions, affecting more than 12 million people daily in the US alone. STA-363 is presumed to last the patient’s entire life and require no extensive rehabilitation. The product vision of STA-363 is to become the new standard of care for patients with discogenic cLBP.